Attention Deficit / Hyperactivity Disorder (ADHD).
Rubicrono® is indicated as part of a comprehensive treatment program for Attention Deficit Hyperactivity Disorder (ADHD) in children from 6 years of age when other measures, by themselves, have proven to be insufficient. The treatment should be under the supervision of a specialist in behavioral disorders in children. The diagnosis must be made according to the current DSM criteria or the guidelines of the CIE and must be based on the complete history and evaluation of the patient. The diagnosis can not be established only with the presence of one or more symptoms.
In adolescents whose symptoms persist until adulthood and who have shown a clear benefit with the treatment, it may be appropriate to continue with it in adulthood. However, it is not appropriate to start treatment with Rubicrono in adults.
Download sheetHigh-density polyethylene (HDPE) bottles with polypropylene child-resistant closure and silica gel desiccant inserted in the lid, RUBICRONO® is marketed in:
18 mg: 30 prolonged-release tablets.
27 mg: 30 prolonged-release tablets.
36 mg: 30 prolonged-release tablets.
54 mg: 30 prolonged-release tablets.
